ADIPOQ -11391G>C

The Adiponectin Promoter Switch — When Your Gene Runs Quiet

Adiponectin is the most abundant adipokine the body produces, secreted almost exclusively
by fat tissue and acting as a master regulator of insulin sensitivity | a hormone that activates
AMPK in muscle and liver, suppresses hepatic glucose output, and reduces inflammation throughout
the vascular system. The ADIPOQ gene's promoter
region — the molecular switch that determines how actively the gene is transcribed — contains
several functional variants that alter circulating adiponectin levels. The rs266729 variant sits
approximately 11,391 base pairs upstream of the ADIPOQ transcription start site, where a
C-to-G substitution at this position demonstrably dampens gene expression and lowers adiponectin
output in carriers.

This SNP is catalogued at dbSNP as a 2 KB upstream regulatory variant at chromosome 3
position 186,841,685 (GRCh38). The G allele has been consistently identified across independent
meta-analyses as a low-penetrant but replicable risk factor for type 2 diabetes, non-alcoholic
fatty liver disease, and cardiovascular disease — driven primarily by reduced adiponectin
transcription that impairs the body's natural insulin-sensitizing and anti-inflammatory
signalling.

The Mechanism

The rs266729 C>G substitution alters a transcription factor binding site | proteins that attach
to specific DNA sequences and drive or repress gene expression
in the ADIPOQ proximal promoter. Electrophoretic mobility shift assays have demonstrated that
the G allele reduces the binding affinity of activating transcription factors at this site,
lowering ADIPOQ transcriptional activity relative to the C allele. The downstream consequence
is reduced circulating adiponectin — particularly the high-molecular-weight (HMW) multimeric
form that drives insulin sensitisation and vascular protection.

Adiponectin signals through two receptors: AdipoR1 | predominantly in skeletal muscle;
activates AMPK to increase fatty acid oxidation and glucose uptake
and AdipoR2 | predominantly in liver; activates PPARα to reduce lipid accumulation and
hepatic inflammation. When adiponectin
levels are chronically low because the promoter runs quiet, both pathways are under-activated:
insulin sensitivity falls, hepatic fat accumulates, vascular inflammation rises, and the risk
of metabolic disease increases across multiple organ systems.

The Evidence

The landmark meta-analysis by Sun et al. | 7 studies, 12,323 total subjects
established that the G allele increases T2D risk with a generalized odds ratio of 1.13
(95% CI 1.02–1.25) and an additive model OR of 1.13 per G allele (95% CI 1.06–1.19).
An earlier meta-analysis by Gong et al. | 10,267 T2D cases and 12,837 controls across multiple
ethnicities found a very similar estimate: G allele
OR 1.08 (95% CI 1.01–1.15, P=0.034), classifying rs266729 as "a low-penetrant risk factor for
developing T2D."

Cardiovascular risk is compounded. A comprehensive meta-analysis by Kanu et al. | 65 studies,
19,106 CVD cases and 31,629 controls found
significant increases in cardiovascular disease risk for rs266729 in both the dominant and
heterozygote genetic models. Trial sequential analysis confirmed sufficient evidence "to reach
concrete conclusions."

Non-alcoholic fatty liver disease (NAFLD) shows particularly strong genotype-dose effects.
Zheng et al. | systematic review and meta-analysis, 2,619 NAFLD cases and 1,962 controls
across 10 studies found that the G allele
nearly doubled NAFLD risk in the allelic model (OR 1.72, 95% CI 1.34–2.21) and that GG
homozygotes faced a 2.69-fold risk increase (95% CI 1.84–3.92). Associations were consistent
across Asian and Caucasian populations.

At the tissue level, Divella et al. demonstrated
in colorectal cancer patients that CG and GG carriers have significantly lower circulating
adiponectin than CC homozygotes (P=0.034), confirming the functional consequence of the
transcriptional impairment. G allele carriers also showed elevated TNF-α, connecting reduced
adiponectin to heightened inflammatory signalling.

Practical Actions

The rs266729 G allele's primary effect is reduced adiponectin output, which means interventions
that naturally boost adiponectin expression are particularly relevant. Omega-3 fatty acids
(EPA and DHA) activate PPARγ in adipocytes | the master transcriptional regulator of adipogenesis
and adiponectin secretion, stimulating ADIPOQ
transcription and partially compensating for reduced promoter activity. In randomised trials,
3–4 g/day EPA/DHA supplementation raises adiponectin by 10–25% in insulin-resistant individuals.

Dietary fat composition also modulates ADIPOQ expression through PPARγ. Monounsaturated fatty
acids (olive oil, avocados, almonds) and polyunsaturated fats preferentially activate PPARγ,
while saturated fat suppresses it. For G allele carriers whose promoter is already operating
at reduced capacity, minimising saturated fat and replacing it with MUFA or PUFA has the most
evidence for raising adiponectin toward protective levels.

Monitoring adiponectin levels directly is meaningful for this genotype — particularly if other
metabolic risk factors are present. Low adiponectin (<5 µg/mL in men, <8 µg/mL in women)
substantially amplifies the risk of the associated conditions, and tracking changes in response
to dietary intervention gives direct feedback on whether the compensation is working.

Interactions

rs266729 is in moderate-to-high linkage disequilibrium with rs17300539 (-11391G>A), the other
functional ADIPOQ promoter SNP already on the platform, as well as with rs2241766 (+45T>G,
Gly15Gly in exon 2) and rs1501299 (+276G>T, intron 2). Haplotype combinations across these
four variants produce stronger effects on adiponectin levels than any single SNP alone — the
A-C haplotype combining rs17300539-A and rs266729-C is associated with greater adiponectin
elevation and better lipid outcomes after bariatric surgery than either allele alone.

Emerging data suggest interaction with TCF7L2 variants (particularly rs7903146): TCF7L2
regulates adipocyte differentiation and function, and the combination of TCF7L2 T-allele risk
with reduced adiponectin from rs266729 G-allele may identify individuals with the highest
dietary fat sensitivity. This interaction candidate is described for supervisor review.